National Lung Cancer Audit

Summary of results for patients diagnosed in England 2022

Diagnosis & staging

36,886 patients were diagnosed with lung cancer in 2022

34,235 in 2021 , **31,371** in 2020
33,091 in 2019

74 years — age at diagnosis (median)

84% of patients **with stage I/II disease, performance status (PS) 0-1** had pathological confirmation of their diagnosis
83% in 2021, **77%** in 2020 & **84%** in 2019

45% of patients presented **with stage IV disease**
48% in 2021, **50%** in 2020 & **47%** in 2019

32% of patients were diagnosed **via emergency presentation**
35% in 2021, **35%** in 2020 & **31%** in 2019

Key
- improving from 2021
- worsening from 2021
- unchanged from 2021

93% of patients* were assessed at diagnosis by a **lung cancer clinical nurse specialist:**
92% in 2021, **75%** in 2020 and **80%** in 2019

≥90% ? Audit standard*

*information available for 60% of patients so this is uncertain

Treatment allocation

Surgery for non-small cell lung cancer (NSCLC)

18% of patients with NSCLC had surgical treatment for their cancer

≥17% Audit standard

17% in 2021
15% in 2020
20% in 2019

Chemotherapy for small cell lung cancer (SCLC)

71% of patients with SCLC received treatment with chemotherapy



≥70% Audit standard

72% in 2021
66% in 2020
69% in 2019

Treatment with curative intent

78% of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative intent**

≥80% Audit standard

80% in 2021
73% in 2020
81% in 2019

59% of patients with NSCLC (stage IIIA, PS 0-2) received treatment with curative intent***

N/A

61% in 2021
51% in 2020
57% in 2019

**surgery or radical radiotherapy

***surgery, radical radiotherapy or multimodal combination with chemotherapy

Systemic anti-cancer therapy

60% of patients with NSCLC (stage IIIB/IV, PS 0-1) received systemic anticancer therapy

≥70% Audit standard

63% in 2021
55% in 2020
54% in 2019

Survival outcomes

17,564 patients were diagnosed between 1 January and 30 June 2022. For these patients:

Median survival

327 days

280 days in 2021
306 days in 2020
316 days in 2019

One year survival

48%

44% in 2021
44% in 2020
41% in 2019

Data quality

Completeness of key routine data items

Stage	Performance status	Morphology	Basis of diagnosis	CNS at diagnosis	Smoking status
89%	83%	67%	92%	60%	48%
90% Audit standard	90% Audit standard	75% Audit standard	90% Audit standard	90% Audit standard	90% Audit standard
86% in 2021	83% in 2021	65% in 2021	90% in 2021	59% in 2021	49% in 2021

National Lung Cancer Audit

Summary of results for patients diagnosed in Wales 2022

Diagnosis & staging

2,211 patients were diagnosed with lung cancer in 2022

2,244 in 2021, **2,067** in 2020
2,240 in 2019

74 years — age at diagnosis (median)

89% of patients **with stage I/II disease, performance status (PS) 0-1** had pathological confirmation of their diagnosis
85% in 2021, **83%** in 2020 & **86%** in 2019

47% of patients presented **with stage IV disease**
50% in 2021, **49%** in 2020 & **48%** in 2019

29% of patients were diagnosed **via emergency presentation**
24% in 2021, **28%** in 2020 & **29%** in 2019

Key
- improving from 2021
- worsening from 2021
- unchanged from 2021

92% of patients* were assessed at diagnosis by a **lung cancer clinical nurse specialist:**
94% in 2021, **93%** in 2020 and **95%** in 2019

≥90% Audit standard*

Treatment allocation

Surgery for non-small cell lung cancer (NSCLC)

14% of patients with NSCLC had surgical treatment for their cancer



≥17% Audit standard

13% in 2021
11% in 2020
15% in 2019

Chemotherapy for small cell lung cancer (SCLC)

71% of patients with SCLC received treatment with chemotherapy



≥70% Audit standard

71% in 2021
58% in 2020
65% in 2019

Treatment with curative intent

76% of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative intent**

≥80% Audit standard

67% in 2021
68% in 2020
74% in 2019

**surgery or radical radiotherapy

61% of patients with NSCLC (stage IIIA, PS 0-2) received treatment with curative intent***

N/A

61% in 2021
48% in 2020
56% in 2019

***surgery, radical radiotherapy or multimodal combination with chemotherapy

Systemic anti-cancer therapy

60% of patients with NSCLC (stage IIIB - IV, PS 0-1) received systemic anticancer therapy

≥70% Audit standard

57% in 2021
53% in 2020
55% in 2019

Survival outcomes

2,211 patients were diagnosed between 1 January and 31 December 2022. For these patients:

Median survival

262 days

222 days in 2021
224 days in 2020
235 days in 2019

One year survival

43%

39% in 2021
40% in 2020
42% in 2019

Data quality

Completeness of key routine data items***

***information on smoking status unavailable

Stage	Performance status	Morphology	Basis of diagnosis	CNS at diagnosis
99%	98%	100%	100%	99%
90% Audit standard	90% Audit standard	75 % Audit standard	90% Audit standard	90% Audit standard
98% in 2021	97% in 2021	100% in 2021	100% in 2021	98% in 2021